A facile adenosine triphosphate‑responsive nanoplatform for efficacious therapy of esophageal cancer
- Jinglong Wang
- Linhao Xu
- Xiaotong Liu
- Ronghua Yang
- Dong Wang
Affiliations: Department of Thoracic Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China
- Published online on: August 10, 2020 https://doi.org/10.3892/ol.2020.11969
Copyright: © Wang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Current chemotherapeutic agents against esophageal cancer (EC) are suboptimal. To improve treatment efficacy, a nanoplatform based on ATP‑responsive drug release was developed for EC therapy. First, the chemotherapeutic agent epirubicin (EPI) was inserted into an ATP aptamer (Ap) to form double‑stranded DNA (‘DNA duplex’). Subsequently, polyethyleneimine (PEI) was employed to condense the EPI‑loaded duplex to construct the final nanoplatform (PEI‑Ap‑EPI). Following internalization by cancer cells, the EPI‑loaded DNA duplex could open and release EPI in an intracellular ATP‑rich environment. An in vitro drug‑release assay demonstrated that ~50% of EPI was released from PEI‑Ap‑EPI in an ATP‑rich condition. However, only 15% of EPI was released in the presence of a low concentration of ATP. In vitro cytotoxicity and apoptosis assays demonstrated that PEI‑Ap‑EPI could enhance EPI efficiency against EC cells markedly compared with those in the control group. Therefore, this facile PEI‑Ap‑EPI nanoplatform may be a promising strategy to improve the efficacy of EPI treatment in EC.